Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
BDC-3042 in Ovarian Cancer: NCT06052852 Clinical Landscape Report 2026
9 min read
BDC-3042 in Ovarian Cancer: NCT06052852 Clinical Landscape Report 2026
16 October 2026
NCT06052852 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
177Lu-PSMA-1 in Metastatic Clear Cell Renal Cell Carcinoma: NCT06059014 Clinical Landscape Report 2026
9 min read
177Lu-PSMA-1 in Metastatic Clear Cell Renal Cell Carcinoma: NCT06059014 Clinical Landscape Report 2026
16 October 2026
NCT06059014 clinical landscape for Metastatic Clear Cell Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development…
Read →
Fluzoparib in Ovarian Cancer: NCT06063070 Clinical Landscape Report 2026
9 min read
Fluzoparib in Ovarian Cancer: NCT06063070 Clinical Landscape Report 2026
16 October 2026
NCT06063070 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Selinexor in Diffuse Large B-Cell Lymphoma: NCT06062641 Clinical Landscape Report 2026
9 min read
Selinexor in Diffuse Large B-Cell Lymphoma: NCT06062641 Clinical Landscape Report 2026
16 October 2026
NCT06062641 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
TROP2-CAR-NK(M.D. Anderson Cancer Center) in Locally Advanced Malignant Solid Neoplasm: NCT06066424 Clinical Landscape Report 2026
9 min read
TROP2-CAR-NK(M.D. Anderson Cancer Center) in Locally Advanced Malignant Solid Neoplasm: NCT06066424 Clinical Landscape Report 2026
16 October 2026
NCT06066424 clinical landscape for Locally Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development w…
Read →
Vusolimogene oderparepvec-wtpg in Triple Negative Breast Cancer: NCT06067061 Clinical Landscape Report 2026
9 min read
Vusolimogene oderparepvec-wtpg in Triple Negative Breast Cancer: NCT06067061 Clinical Landscape Report 2026
16 October 2026
NCT06067061 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Semaglutide (Novo Nordisk) in Endometrial Carcinoma: NCT06073184 Clinical Landscape Report 2026
9 min read
Semaglutide (Novo Nordisk) in Endometrial Carcinoma: NCT06073184 Clinical Landscape Report 2026
16 October 2026
NCT06073184 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Ifupinostat in Diffuse Large B-Cell Lymphoma: NCT06074107 Clinical Landscape Report 2026
9 min read
Ifupinostat in Diffuse Large B-Cell Lymphoma: NCT06074107 Clinical Landscape Report 2026
16 October 2026
NCT06074107 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Polatuzumab Vedotin-Piiq in Large B-cell lymphoma: NCT06071871 Clinical Landscape Report 2026
9 min read
Polatuzumab Vedotin-Piiq in Large B-cell lymphoma: NCT06071871 Clinical Landscape Report 2026
16 October 2026
NCT06071871 clinical landscape for Large B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Carboplatin in Endometrial Carcinoma: NCT06066216 Clinical Landscape Report 2026
9 min read
Carboplatin in Endometrial Carcinoma: NCT06066216 Clinical Landscape Report 2026
16 October 2026
NCT06066216 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Mefuparib Hydrochloride in Solid tumor: NCT06078670 Clinical Landscape Report 2026
9 min read
Mefuparib Hydrochloride in Solid tumor: NCT06078670 Clinical Landscape Report 2026
16 October 2026
NCT06078670 clinical landscape for Solid tumor: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Cyclophosphamide in Breast Cancer: NCT06072612 Clinical Landscape Report 2026
9 min read
Cyclophosphamide in Breast Cancer: NCT06072612 Clinical Landscape Report 2026
16 October 2026
NCT06072612 clinical landscape for Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →